SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Depotech(depo) -- Ignore unavailable to you. Want to Upgrade?

To: scott harrison who wrote (252)11/23/1997 2:50:00 PM
From: Tom D  Read Replies (1) | Respond to of 887
 
Scott, let me make a suggestion.

If you have time, please look through some of my earlier posts. Over the last two months I have posted volumes of information about every apsect of DepoCyt that has ever flashed through the neural jungles of my mind. For example, posting #117 has revenue estimates for each of the next few years based on full FDA approval in early Q1 '98. Posting #118 fleshes out some of the details which form the basis of those estimates.

You can also obtain copies of detailed analyst reports from IR at DEPO--free if you ask specifically for them. And tell Dana I saild hello.

Best Regards,

Tom D



To: scott harrison who wrote (252)11/23/1997 3:03:00 PM
From: scaram(o)uche  Respond to of 887
 
Scott:

I'm not sure of what your question actually addresses. However, the analyst that I respect most who follows DEPO is Michael King of Vector Securities. He assures clients that production issues do not exist, that preinspections by FDA have been exhaustive, and that DepoCyt is ready for launch.

Rick


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News